EverQuote vs Humana

10-Q Financial Filing Analysis for EverQuote (2026-08-04)

EverQuote, Inc. reported solid financial results for the second quarter ended June 30, 2026, with total revenue rising 24.6% year-over-year to $195.1 million, driven by strong auto carrier demand and referral spend. Operating income reached $23.5 million compared to $14.2 million in Q2 2025, and net income increased to $19.2 million ($0.53 diluted EPS). Adjusted EBITDA expanded 37.1% year-over-year to $30.1 million, while Variable Marketing Margin (VMM) remained healthy at 29.2%. During the quarter, EverQuote completed its $50.0 million share repurchase program, repurchasing an additional 578,322 shares of Class A common stock for $9.1 million. The company's liquidity remains strong, with $192.3 million in cash and cash equivalents and zero debt outstanding under its $60.0 million revolving credit facility. The performance reflects continuing recovery and operational leverage in property and casualty direct distribution channels.

• Q2 2026 total revenue increased 24.6% YoY to $195.1 million, with Automotive vertical revenue up 23.3% to $172.1 million and Home & Renters revenue up 35.2% to $23.0 million.
• Net income for the quarter reached $19.2 million ($0.53 diluted EPS), with Adjusted EBITDA growing 37.1% to $30.1 million and cash flow from operations generating $53.9 million for the first half of 2026.
• Completed the board-authorized $50.0 million share repurchase program, repurchasing 578,322 shares for $9.1 million in Q2 2026, while ending the quarter with $192.3 million in cash and cash equivalents.

Investor Presentation Released: EverQuote

AI parsed presentation narrative: Management is actively engaging with investors across multiple industry-focused conferences to highlight EverQuote's role as a leading AI-powered growth partner for the P&C insurance industry. The company aims to demonstrate how its proprietary data assets and AI traffic engine drive customer acquisition for carriers and agents. Key tailwinds mentioned: AI-Powered Customer Acquisition, Digital Transformation in P&C Insurance.

8-K Financial Filing Analysis for Humana (2026-10-13)

On October 13, 2026, Humana Inc. announced a new joint venture arrangement with funds managed by HPS Investment Partners, a subsidiary of BlackRock, Inc., to manage and operate its CenterWell Senior Primary Care clinic network. This arrangement replaces CenterWell's existing joint venture with Welsh, Carson, Anderson & Stowe (WCAS), with BlackRock acquiring WCAS's equity stake under modified terms. Notably, the new JV eliminates the previous put option held by WCAS, resulting in an expected significant reduction in balance sheet liabilities and a lower overall cost of capital. Concurrently, Humana reaffirmed its FY 2026 Adjusted EPS guidance of at least $9.00.

• BlackRock subsidiary HPS Investment Partners acquired WCAS's equity stake in CenterWell Senior Primary Care clinics under a restructured joint venture eliminating previous put option liabilities.
• CenterWell secures the option to purchase clinics starting in 2028, with BlackRock holding exit rights via a sale process by end-2033 if clinics remain unacquired.
• Humana reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 per common share.

8-K Financial Filing Analysis for Humana (2026-10-09)

Humana Inc. announced that it has exceeded its goal of Top Quartile results for the 2027 Medicare Advantage (MA) Star Ratings (Bonus Year 2028), based on final data released by the Centers for Medicare and Medicaid Services (CMS) on October 8, 2026. Top Quartile performance is defined as Stars revenue per member per month (PMPM) at least 10% above the peer group median. While anticipating that a portion of the 2028 bonus outperformance will be one-time in nature, Humana expects to utilize the resulting financial benefit for one-time investments and capital returns to shareholders. Concurrently, the company reaffirmed its full-year 2026 Adjusted EPS guidance of at least $9.00 and announced a virtual investor update scheduled for December 10, 2026.

• Exceeded the Top Quartile target for 2027 CMS Medicare Advantage Star Ratings (Bonus Year 2028), defined as Stars revenue PMPM 10% above the peer group median.
• Reaffirmed full-year 2026 Adjusted EPS guidance of at least $9.00 per share.
• Scheduled a virtual investor update for December 10, 2026, to review progress against the multi-year earnings framework through 2028.

Humana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027

Press Release | 10/01/2026 Humana Maintains Affordable Medicare Advantage Plans and Expands Specialized Care Options for 2027